TG Therapeutics IncNASDAQ:TGTX
- LAST PRICE13.8300
- TODAY'S CHANGE (%)-0.1600 (-1.1437%)
- Bid / Lots13.8200/ 2
- Ask / Lots13.8300/ 3
- Open / Previous Close13.8700 / 13.9900
- Day Range
- 52 Week Range
- Volume354,230
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TGTX |
|---|---|---|
| 09:32 ET | 64020 | 13.97 |
| 09:34 ET | 6478 | 13.91 |
| 09:36 ET | 38494 | 14 |
| 09:38 ET | 19944 | 13.8502 |
| 09:39 ET | 9575 | 13.83 |
| 09:41 ET | 36410 | 13.82 |
| 09:43 ET | 8104 | 13.83 |
| 09:45 ET | 31738 | 13.83 |
| 09:48 ET | 27354 | 13.87 |
| 09:50 ET | 9332 | 13.885 |
| 09:52 ET | 17793 | 13.91 |
| 09:54 ET | 4197 | 13.87 |
| 09:56 ET | 6150 | 13.875 |
| 09:57 ET | 22217 | 13.825 |
| 09:59 ET | 1885 | 13.83 |
Yesterday
DJ TG Therapeutics Price Target Maintained With a $45.00/Share by HC Wainwright & Co., from 20 hours ago by Dow Jones
20 hours ago by Dow JonesDJ TG Therapeutics Price Target Maintained With a $25.00/Share by JP Morgan, from 20 hours ago by Dow Jones
20 hours ago by Dow JonesDJ TG Therapeutics Price Target Maintained With a $39.00/Share by Ladenburg Thalmann, from 20 hours ago by Dow Jones
20 hours ago by Dow JonesTG Therapeutics Announces Additional Data Presentations for BRIUMVI(R) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting, from 7:30AM ET on Thursday Apr 18, 2024 by Dow Jones
7:30AM ET on Thursday Apr 18, 2024 by Dow JonesTG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis, from 7:00AM ET on Thursday Apr 18, 2024 by Dow Jones
7:00AM ET on Thursday Apr 18, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TG Therapeutics Inc | 2.2B | 979.5x | --- |
Vericel Corp | 2.1B | -647.4x | --- |
Ginkgo Bioworks Holdings Inc | 1.9B | -2.0x | --- |
Maravai LifeSciences Holdings Inc | 1.9B | -8.4x | --- |
Twist Bioscience Corp | 1.6B | -8.1x | --- |
Immunocore Holdings PLC | 2.7B | -49.1x | --- |
Company Information
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact Information
- Headquarters
- 3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
- Phone
- 212-554-4484
- Fax
- 212-554-4531
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Weiss
- Chief Financial Officer, Treasurer, Corporate Secretary
- Sean Power
- Lead Independent Director
- Laurence Charney
- Independent Director
- Yann Echelard
- Independent Director
- Kenneth Hoberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
|---|---|
Revenue (TTM) | $233.7M |
Shares Outstanding | 154.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.31 |
EPS | $0.01 |
Book Value | $1.06 |
P/E Ratio | 979.5x |
Price/Sales (TTM) | 9.2 |
Price/Cash Flow (TTM) | 167.7x |
Operating Margin | 8.83% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
